Literature DB >> 27925328

Screening for pre-eclampsia in the first trimester: role of maternal hemodynamics and bioimpedance in non-obese patients.

G Gagliardi1, G M Tiralongo1,2, D LoPresti1,2, I Pisani1,2, D Farsetti1,2, B Vasapollo1, G P Novelli3, A Andreoli4, H Valensise1,2.   

Abstract

OBJECTIVE: To test if maternal hemodynamics and bioimpedance, assessed at the time of combined screening for PE, are able to identify in the first trimester of gestation normotensive non-obese patients at risk for pre-eclampsia (PE) and/or intrauterine growth restriction (IUGR).
METHODS: One hundred and fifty healthy nulliparous non-obese women (body mass index < 30 kg/m2 ) in the first trimester of pregnancy underwent assessment by UltraSonic Cardiac Output Monitor (USCOM) to detect hemodynamic parameters, bioimpedance analysis to characterize body composition, and combined screening for PE (assessment of maternal history, biophysical and maternal biochemical markers). Patients were followed until term, noting the appearance of PE and/or IUGR.
RESULTS: One hundred and thirty-eight patients had an uneventful pregnancy (controls), while 12 (8%) developed complications (cases). USCOM showed, in cases compared with controls, lower cardiac output (5.6 ± 0.3 vs 6.7 ± 1.1 L/min, P < 0.001), lower inotropy index (1.54 ± 0.38 vs 1.91 ± 0.32 W/m2 , P < 0.001) and higher total vascular resistance (1279.8 ± 166.4 vs 1061.4 ± 179.5 dynes × s/cm5 , P < 0.001). Bioimpedance analysis showed, in cases compared with controls, lower total body water (53.7 ± 3.3% vs 57.2 ± 5.6%, P = 0.037). Combined screening was positive for PE in 8% of the controls and in 50% of the cases (P < 0.001). After identification of cut-off values for USCOM and bioimpedance parameters, forward multivariate logistic regression analysis identified as independent predictors of complications in pregnancy the inotropy index (derived by USCOM), fat mass (derived from bioimpedance analysis) and combined screening.
CONCLUSIONS: Combined screening for PE and assessment of bioimpedance and maternal hemodynamics can be used to identify early markers of impaired cardiovascular adaptation and body composition that may lead to complications in the third trimester of pregnancy.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bioimpedance; cardiac function; combined screening; first trimester; hemodynamics; pre-eclampsia

Mesh:

Substances:

Year:  2017        PMID: 27925328     DOI: 10.1002/uog.17379

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  4 in total

Review 1.  Hypertensive disorders and maternal hemodynamic changes in pregnancy: monitoring by USCOM® device.

Authors:  Elisa Montaguti; Gaetana Di Donna; Aly Youssef; Gianluigi Pilu
Journal:  J Med Ultrason (2001)       Date:  2022-06-15       Impact factor: 1.878

2.  Awareness of obstetricians for long-term risks in women with a history of preeclampsia or HELLP syndrome.

Authors:  Pilar Palmrich; Carina Binder; Harald Zeisler; Bettina Kroyer; Petra Pateisky; Julia Binder
Journal:  Arch Gynecol Obstet       Date:  2021-08-18       Impact factor: 2.344

Review 3.  Association between maternal adiposity measures and adverse maternal outcomes of pregnancy: Systematic review and meta-analysis.

Authors:  Nicola Heslehurst; Lem Ngongalah; Theophile Bigirumurame; Giang Nguyen; Adefisayo Odeniyi; Angela Flynn; Vikki Smith; Lisa Crowe; Becky Skidmore; Laura Gaudet; Alexandre Simon; Louise Hayes
Journal:  Obes Rev       Date:  2022-04-25       Impact factor: 10.867

4.  Study protocol for a prospective cohort study to investigate Hemodynamic Adaptation to Pregnancy and Placenta-related Outcome: the HAPPO study.

Authors:  Rianne C Bijl; Jérôme M J Cornette; Annemien E van den Bosch; Johannes J Duvekot; Jeroen Molinger; Sten P Willemsen; Anton H J Koning; Jolien W Roos-Hesselink; Arie Franx; Régine P M Steegers-Theunissen; Maria P H Koster
Journal:  BMJ Open       Date:  2019-11-10       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.